Review



mapk pathway involvement  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc mapk pathway involvement
    ESK inhibits <t>MAPK</t> pathway activation in the SDH of BCP rats. ( A–D ) Representative WB images and quantification of <t>phosphorylated</t> <t>JNK</t> ( B ), p38 ( C ), and ERK ( D ) levels. Data are mean ± SEM of biological replicates n = 3. *** P < 0.001 versus sham plus vehicle group, # P < 0.05, ## P < 0.01, ### P < 0.001 versus BCP plus vehicle group, ns, not significant. One-way ANOVA with repeated measures followed by post hoc Tukey test. ( E ) Schematic of experimental timeline showing repeated intrathecal administration of ESK, SB203580 (p38 inhibitor), or SP600125 (JNK inhibitor) on POD 13 to 16. ( F ) Co-treatment with ESK enhanced the MAPK inhibitors induced increase in PWT after intrathecal administration. Notably, co-administration of MAPK inhibitors did not further enhance ESK’s analgesic effect, suggesting that its antinociceptive action mainly involves MAPK pathway inhibition. Data are mean ± SEM of biological replicates n = 7–8 rats/group. Two-way ANOVA with repeated measures followed by post hoc Tukey test. * P < 0.05, ** P < 0.01, *** P < 0.001 vs. BCP + DMSO; # P < 0.05, BCP + ESK+SB203580 vs. BCP + SB203580, BCP + ESK+SP600125 vs. BCP + SP600125 at corresponding time points. ( G ) Western blot of IL-1β, IL-6, and TNF-α expression in the SDH. ( H–J ) Quantification of cytokine levels showed further reductions in IL-1β ( H ), IL-6 ( I ), and TNF-α ( J ) with combined ESK and MAPK inhibitor treatment. Data are mean ± SEM of biological replicates n = 3. * P < 0.05, ** P < 0.01, *** P < 0.001, ns, not significant. One-way ANOVA with repeated measures followed by post hoc Tukey test.
    Mapk Pathway Involvement, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 709 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mapk pathway involvement/product/Cell Signaling Technology Inc
    Average 96 stars, based on 709 article reviews
    mapk pathway involvement - by Bioz Stars, 2026-05
    96/100 stars

    Images

    1) Product Images from "Esketamine attenuates bone cancer pain by suppressing MAPK signaling and glial activation in the spinal dorsal horn of rats"

    Article Title: Esketamine attenuates bone cancer pain by suppressing MAPK signaling and glial activation in the spinal dorsal horn of rats

    Journal: Scientific Reports

    doi: 10.1038/s41598-026-38137-y

    ESK inhibits MAPK pathway activation in the SDH of BCP rats. ( A–D ) Representative WB images and quantification of phosphorylated JNK ( B ), p38 ( C ), and ERK ( D ) levels. Data are mean ± SEM of biological replicates n = 3. *** P < 0.001 versus sham plus vehicle group, # P < 0.05, ## P < 0.01, ### P < 0.001 versus BCP plus vehicle group, ns, not significant. One-way ANOVA with repeated measures followed by post hoc Tukey test. ( E ) Schematic of experimental timeline showing repeated intrathecal administration of ESK, SB203580 (p38 inhibitor), or SP600125 (JNK inhibitor) on POD 13 to 16. ( F ) Co-treatment with ESK enhanced the MAPK inhibitors induced increase in PWT after intrathecal administration. Notably, co-administration of MAPK inhibitors did not further enhance ESK’s analgesic effect, suggesting that its antinociceptive action mainly involves MAPK pathway inhibition. Data are mean ± SEM of biological replicates n = 7–8 rats/group. Two-way ANOVA with repeated measures followed by post hoc Tukey test. * P < 0.05, ** P < 0.01, *** P < 0.001 vs. BCP + DMSO; # P < 0.05, BCP + ESK+SB203580 vs. BCP + SB203580, BCP + ESK+SP600125 vs. BCP + SP600125 at corresponding time points. ( G ) Western blot of IL-1β, IL-6, and TNF-α expression in the SDH. ( H–J ) Quantification of cytokine levels showed further reductions in IL-1β ( H ), IL-6 ( I ), and TNF-α ( J ) with combined ESK and MAPK inhibitor treatment. Data are mean ± SEM of biological replicates n = 3. * P < 0.05, ** P < 0.01, *** P < 0.001, ns, not significant. One-way ANOVA with repeated measures followed by post hoc Tukey test.
    Figure Legend Snippet: ESK inhibits MAPK pathway activation in the SDH of BCP rats. ( A–D ) Representative WB images and quantification of phosphorylated JNK ( B ), p38 ( C ), and ERK ( D ) levels. Data are mean ± SEM of biological replicates n = 3. *** P < 0.001 versus sham plus vehicle group, # P < 0.05, ## P < 0.01, ### P < 0.001 versus BCP plus vehicle group, ns, not significant. One-way ANOVA with repeated measures followed by post hoc Tukey test. ( E ) Schematic of experimental timeline showing repeated intrathecal administration of ESK, SB203580 (p38 inhibitor), or SP600125 (JNK inhibitor) on POD 13 to 16. ( F ) Co-treatment with ESK enhanced the MAPK inhibitors induced increase in PWT after intrathecal administration. Notably, co-administration of MAPK inhibitors did not further enhance ESK’s analgesic effect, suggesting that its antinociceptive action mainly involves MAPK pathway inhibition. Data are mean ± SEM of biological replicates n = 7–8 rats/group. Two-way ANOVA with repeated measures followed by post hoc Tukey test. * P < 0.05, ** P < 0.01, *** P < 0.001 vs. BCP + DMSO; # P < 0.05, BCP + ESK+SB203580 vs. BCP + SB203580, BCP + ESK+SP600125 vs. BCP + SP600125 at corresponding time points. ( G ) Western blot of IL-1β, IL-6, and TNF-α expression in the SDH. ( H–J ) Quantification of cytokine levels showed further reductions in IL-1β ( H ), IL-6 ( I ), and TNF-α ( J ) with combined ESK and MAPK inhibitor treatment. Data are mean ± SEM of biological replicates n = 3. * P < 0.05, ** P < 0.01, *** P < 0.001, ns, not significant. One-way ANOVA with repeated measures followed by post hoc Tukey test.

    Techniques Used: Activation Assay, Inhibition, Western Blot, Expressing



    Similar Products

    mapk pathway involvement  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc mapk pathway involvement
    ESK inhibits <t>MAPK</t> pathway activation in the SDH of BCP rats. ( A–D ) Representative WB images and quantification of <t>phosphorylated</t> <t>JNK</t> ( B ), p38 ( C ), and ERK ( D ) levels. Data are mean ± SEM of biological replicates n = 3. *** P < 0.001 versus sham plus vehicle group, # P < 0.05, ## P < 0.01, ### P < 0.001 versus BCP plus vehicle group, ns, not significant. One-way ANOVA with repeated measures followed by post hoc Tukey test. ( E ) Schematic of experimental timeline showing repeated intrathecal administration of ESK, SB203580 (p38 inhibitor), or SP600125 (JNK inhibitor) on POD 13 to 16. ( F ) Co-treatment with ESK enhanced the MAPK inhibitors induced increase in PWT after intrathecal administration. Notably, co-administration of MAPK inhibitors did not further enhance ESK’s analgesic effect, suggesting that its antinociceptive action mainly involves MAPK pathway inhibition. Data are mean ± SEM of biological replicates n = 7–8 rats/group. Two-way ANOVA with repeated measures followed by post hoc Tukey test. * P < 0.05, ** P < 0.01, *** P < 0.001 vs. BCP + DMSO; # P < 0.05, BCP + ESK+SB203580 vs. BCP + SB203580, BCP + ESK+SP600125 vs. BCP + SP600125 at corresponding time points. ( G ) Western blot of IL-1β, IL-6, and TNF-α expression in the SDH. ( H–J ) Quantification of cytokine levels showed further reductions in IL-1β ( H ), IL-6 ( I ), and TNF-α ( J ) with combined ESK and MAPK inhibitor treatment. Data are mean ± SEM of biological replicates n = 3. * P < 0.05, ** P < 0.01, *** P < 0.001, ns, not significant. One-way ANOVA with repeated measures followed by post hoc Tukey test.
    Mapk Pathway Involvement, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mapk pathway involvement/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    mapk pathway involvement - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier
    mapk signaling pathways involving p38, extracellular-signal-regulated kinase (erk), and c-jun n-terminal kinase (jnk)  (Hamad Medical Corporation)
    90
    Hamad Medical Corporation mapk signaling pathways involving p38, extracellular-signal-regulated kinase (erk), and c-jun n-terminal kinase (jnk)
    ESK inhibits <t>MAPK</t> pathway activation in the SDH of BCP rats. ( A–D ) Representative WB images and quantification of <t>phosphorylated</t> <t>JNK</t> ( B ), p38 ( C ), and ERK ( D ) levels. Data are mean ± SEM of biological replicates n = 3. *** P < 0.001 versus sham plus vehicle group, # P < 0.05, ## P < 0.01, ### P < 0.001 versus BCP plus vehicle group, ns, not significant. One-way ANOVA with repeated measures followed by post hoc Tukey test. ( E ) Schematic of experimental timeline showing repeated intrathecal administration of ESK, SB203580 (p38 inhibitor), or SP600125 (JNK inhibitor) on POD 13 to 16. ( F ) Co-treatment with ESK enhanced the MAPK inhibitors induced increase in PWT after intrathecal administration. Notably, co-administration of MAPK inhibitors did not further enhance ESK’s analgesic effect, suggesting that its antinociceptive action mainly involves MAPK pathway inhibition. Data are mean ± SEM of biological replicates n = 7–8 rats/group. Two-way ANOVA with repeated measures followed by post hoc Tukey test. * P < 0.05, ** P < 0.01, *** P < 0.001 vs. BCP + DMSO; # P < 0.05, BCP + ESK+SB203580 vs. BCP + SB203580, BCP + ESK+SP600125 vs. BCP + SP600125 at corresponding time points. ( G ) Western blot of IL-1β, IL-6, and TNF-α expression in the SDH. ( H–J ) Quantification of cytokine levels showed further reductions in IL-1β ( H ), IL-6 ( I ), and TNF-α ( J ) with combined ESK and MAPK inhibitor treatment. Data are mean ± SEM of biological replicates n = 3. * P < 0.05, ** P < 0.01, *** P < 0.001, ns, not significant. One-way ANOVA with repeated measures followed by post hoc Tukey test.
    Mapk Signaling Pathways Involving P38, Extracellular Signal Regulated Kinase (Erk), And C Jun N Terminal Kinase (Jnk), supplied by Hamad Medical Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mapk signaling pathways involving p38, extracellular-signal-regulated kinase (erk), and c-jun n-terminal kinase (jnk)/product/Hamad Medical Corporation
    Average 90 stars, based on 1 article reviews
    mapk signaling pathways involving p38, extracellular-signal-regulated kinase (erk), and c-jun n-terminal kinase (jnk) - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    antibodies against various cdks, cyclins, and proteins involved in akt or mapk pathways  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc antibodies against various cdks, cyclins, and proteins involved in akt or mapk pathways
    ESK inhibits <t>MAPK</t> pathway activation in the SDH of BCP rats. ( A–D ) Representative WB images and quantification of <t>phosphorylated</t> <t>JNK</t> ( B ), p38 ( C ), and ERK ( D ) levels. Data are mean ± SEM of biological replicates n = 3. *** P < 0.001 versus sham plus vehicle group, # P < 0.05, ## P < 0.01, ### P < 0.001 versus BCP plus vehicle group, ns, not significant. One-way ANOVA with repeated measures followed by post hoc Tukey test. ( E ) Schematic of experimental timeline showing repeated intrathecal administration of ESK, SB203580 (p38 inhibitor), or SP600125 (JNK inhibitor) on POD 13 to 16. ( F ) Co-treatment with ESK enhanced the MAPK inhibitors induced increase in PWT after intrathecal administration. Notably, co-administration of MAPK inhibitors did not further enhance ESK’s analgesic effect, suggesting that its antinociceptive action mainly involves MAPK pathway inhibition. Data are mean ± SEM of biological replicates n = 7–8 rats/group. Two-way ANOVA with repeated measures followed by post hoc Tukey test. * P < 0.05, ** P < 0.01, *** P < 0.001 vs. BCP + DMSO; # P < 0.05, BCP + ESK+SB203580 vs. BCP + SB203580, BCP + ESK+SP600125 vs. BCP + SP600125 at corresponding time points. ( G ) Western blot of IL-1β, IL-6, and TNF-α expression in the SDH. ( H–J ) Quantification of cytokine levels showed further reductions in IL-1β ( H ), IL-6 ( I ), and TNF-α ( J ) with combined ESK and MAPK inhibitor treatment. Data are mean ± SEM of biological replicates n = 3. * P < 0.05, ** P < 0.01, *** P < 0.001, ns, not significant. One-way ANOVA with repeated measures followed by post hoc Tukey test.
    Antibodies Against Various Cdks, Cyclins, And Proteins Involved In Akt Or Mapk Pathways, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibodies against various cdks, cyclins, and proteins involved in akt or mapk pathways/product/Cell Signaling Technology Inc
    Average 90 stars, based on 1 article reviews
    antibodies against various cdks, cyclins, and proteins involved in akt or mapk pathways - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    ESK inhibits MAPK pathway activation in the SDH of BCP rats. ( A–D ) Representative WB images and quantification of phosphorylated JNK ( B ), p38 ( C ), and ERK ( D ) levels. Data are mean ± SEM of biological replicates n = 3. *** P < 0.001 versus sham plus vehicle group, # P < 0.05, ## P < 0.01, ### P < 0.001 versus BCP plus vehicle group, ns, not significant. One-way ANOVA with repeated measures followed by post hoc Tukey test. ( E ) Schematic of experimental timeline showing repeated intrathecal administration of ESK, SB203580 (p38 inhibitor), or SP600125 (JNK inhibitor) on POD 13 to 16. ( F ) Co-treatment with ESK enhanced the MAPK inhibitors induced increase in PWT after intrathecal administration. Notably, co-administration of MAPK inhibitors did not further enhance ESK’s analgesic effect, suggesting that its antinociceptive action mainly involves MAPK pathway inhibition. Data are mean ± SEM of biological replicates n = 7–8 rats/group. Two-way ANOVA with repeated measures followed by post hoc Tukey test. * P < 0.05, ** P < 0.01, *** P < 0.001 vs. BCP + DMSO; # P < 0.05, BCP + ESK+SB203580 vs. BCP + SB203580, BCP + ESK+SP600125 vs. BCP + SP600125 at corresponding time points. ( G ) Western blot of IL-1β, IL-6, and TNF-α expression in the SDH. ( H–J ) Quantification of cytokine levels showed further reductions in IL-1β ( H ), IL-6 ( I ), and TNF-α ( J ) with combined ESK and MAPK inhibitor treatment. Data are mean ± SEM of biological replicates n = 3. * P < 0.05, ** P < 0.01, *** P < 0.001, ns, not significant. One-way ANOVA with repeated measures followed by post hoc Tukey test.

    Journal: Scientific Reports

    Article Title: Esketamine attenuates bone cancer pain by suppressing MAPK signaling and glial activation in the spinal dorsal horn of rats

    doi: 10.1038/s41598-026-38137-y

    Figure Lengend Snippet: ESK inhibits MAPK pathway activation in the SDH of BCP rats. ( A–D ) Representative WB images and quantification of phosphorylated JNK ( B ), p38 ( C ), and ERK ( D ) levels. Data are mean ± SEM of biological replicates n = 3. *** P < 0.001 versus sham plus vehicle group, # P < 0.05, ## P < 0.01, ### P < 0.001 versus BCP plus vehicle group, ns, not significant. One-way ANOVA with repeated measures followed by post hoc Tukey test. ( E ) Schematic of experimental timeline showing repeated intrathecal administration of ESK, SB203580 (p38 inhibitor), or SP600125 (JNK inhibitor) on POD 13 to 16. ( F ) Co-treatment with ESK enhanced the MAPK inhibitors induced increase in PWT after intrathecal administration. Notably, co-administration of MAPK inhibitors did not further enhance ESK’s analgesic effect, suggesting that its antinociceptive action mainly involves MAPK pathway inhibition. Data are mean ± SEM of biological replicates n = 7–8 rats/group. Two-way ANOVA with repeated measures followed by post hoc Tukey test. * P < 0.05, ** P < 0.01, *** P < 0.001 vs. BCP + DMSO; # P < 0.05, BCP + ESK+SB203580 vs. BCP + SB203580, BCP + ESK+SP600125 vs. BCP + SP600125 at corresponding time points. ( G ) Western blot of IL-1β, IL-6, and TNF-α expression in the SDH. ( H–J ) Quantification of cytokine levels showed further reductions in IL-1β ( H ), IL-6 ( I ), and TNF-α ( J ) with combined ESK and MAPK inhibitor treatment. Data are mean ± SEM of biological replicates n = 3. * P < 0.05, ** P < 0.01, *** P < 0.001, ns, not significant. One-way ANOVA with repeated measures followed by post hoc Tukey test.

    Article Snippet: To assess MAPK pathway involvement, the JNK inhibitor SP600125 (5 μg/10 μl; Cell Signaling Technology, USA) and the p38 inhibitor SB203580 (10 μg/10 μl; Abcam, UK) were dissolved in DMSO to a final DMSO concentration of 1%.

    Techniques: Activation Assay, Inhibition, Western Blot, Expressing